Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | S100B | P04271 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823334 | 1.00 | MAPT (0.53) | MAPTALDH1A1MEN1GAAALOX15 | |
| SCHEMBL29883782 | 0.98 | MAPT (0.50) | MAPTALDH1A1MEN1GAAALOX15 | |
| SCHEMBL13779836 | 0.98 | MAPT (0.50) | MAPTALDH1A1MEN1GAAALOX15 | |
| SCHEMBL3367822 | 0.94 | CHRNB2 (0.47) | MAPTALDH1A1MEN1GAAALOX15 | |
| SCHEMBL2724459 | 0.84 | L3MBTL3 (0.62) | L3MBTL1 | |
| SCHEMBL2821413 | 0.83 | MAPT (0.51) | MAPTALDH1A1MEN1GAAHTT | |
| SCHEMBL16441503 | 0.83 | PIK3CA (0.51) | MAPTALDH1A1MEN1GAAALOX15 | |
| SCHEMBL5658694 | 0.83 | CHRNB2 (0.68) | CHRNB2CHRNA4 | |
| SCHEMBL29150577 | 0.82 | CHRNB2 (0.40) | MAPTKDM4EPOLBCHRNB2CHRNA4 | |
| SCHEMBL13769029 | 0.81 | L3MBTL3 (0.64) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-08-26 | — | — | US | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-115703760-B | 2, 4-Disubstituted pyrimidine cyclin dependent kinase enzyme inhibitor and preparation method and application thereof | 山东大学 | 2024-05-31 | — | — | CN | disclosed |
| EP-4291235-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-111620852-B | 5-chloro-pyrimidine-2, 4-diamine compound, and preparation method and application thereof | 镇江植生源农业科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| CN-115703760-A | 2,4-disubstituted pyrimidines cyclin dependent kinase inhibitor and preparation method and application thereof | 山东大学 | 2023-02-17 | — | — | CN | disclosed |
| CN-115521289-A | Pyridine derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-115448916-A | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-109952303-B | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220259203-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2022-08-18 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3997088-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | Aucentra Therapeutics Pty Ltd (AU) | 2022-05-18 | — | — | EP | disclosed |
| CN-108290864-B | Protein kinase inhibitor and preparation method and medical application thereof | 甘李药业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114269742-A | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amines as therapeutic agents | 常州千红生化制药股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108283644-B | Transient protection of normal cells during chemotherapy | G1治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113956238-A | Protein kinase inhibitor and preparation method and medical application thereof | 甘李药业股份有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259203-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | FLT3, CDK2, CDK4 | MAPT 4006/4885ALDH1A1 2550/4885MEN1 1601/4885 |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | FLT3, CDK2, CDK4 | MAPT 3940/4885ALDH1A1 2406/4885MEN1 1352/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAPT 3895/4885ALDH1A1 4740/4885MEN1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.